Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Citing this Article

Right click to copy or hit: ctrl+c (cmd+c on mac)

Published on 16.07.18 in Vol 5, No 3 (2018): Jul-Sept

This paper is in the following e-collection/theme issue:

Works citing "Software for Administering the National Cancer Institute’s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events: Usability Study"

According to Crossref, the following articles are citing this article (DOI 10.2196/10070):

(note that this is only a small subset of citations)

  1. Li L, Kong F, Zhang L, Li X, Fu X, Wang X, Wu J, Zhang F, Ren L, Zhang M. Apatinib, a novel VEGFR-2 tyrosine kinase inhibitor, for relapsed and refractory nasopharyngeal carcinoma: data from an open-label, single-arm, exploratory study. Investigational New Drugs 2020;
    CrossRef
  2. Huang C, Cheng M, Lee N, Huang H, Lee W, Chang W, Wang P. Comparing Paclitaxel–Carboplatin with Paclitaxel–Cisplatin as the Front-Line Chemotherapy for Patients with FIGO IIIC Serous-Type Tubo-Ovarian Cancer. International Journal of Environmental Research and Public Health 2020;17(7):2213
    CrossRef
  3. Ngai LL, ter Veer E, van den Boorn HG, van Herk EH, van Kleef JJ, van Oijen MGH, van Laarhoven HWM. TOXview: a novel graphical presentation of cancer treatment toxicity profiles. Acta Oncologica 2019;58(8):1138
    CrossRef
  4. Lazarewicz MA, Wlodarczyk D, Lundgren S, Reidunsdatter RJ. Diversity in changes of HRQoL over a 1-year period after radiotherapy in Norwegian breast cancer patients: results of cluster analyses. Quality of Life Research 2019;28(6):1521
    CrossRef
  5. Cheng M, Lee HH, Chang W, Lee N, Huang H, Chen Y, Horng H, Lee W, Wang P. Weekly Dose-Dense Paclitaxel and Triweekly Low-Dose Cisplatin: A Well-Tolerated and Effective Chemotherapeutic Regimen for First-Line Treatment of Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancer. International Journal of Environmental Research and Public Health 2019;16(23):4794
    CrossRef